Abstract: A cooking appliance device includes a heating unit including an induction coil having an electric conductor, a substrate unit, and a fastening unit configured to fasten the induction coil to the substrate unit. The fastening unit fastens the electric conductor in at least one region on the substrate unit such that the electric conductor is movable relative to the substrate unit.

Abstract: The invention relates to a security strip and security paper for obtaining security documents such as legal tender notes, checks or identification documents, comprising a cellulose support web that is completely embedded in a pulp substrate. As both the substrate and the support web are formed by plant fibers, a series of physical and chemical bonds are established between the fibers of both elements, the support web thus being perfectly integrated in the pulp. The cellulose support web will sometimes have a series of security elements, such as pigments, synthetic elements and/or security fibers of the type normally used in this type of application.

Abstract: p38 and JNK mitogen activated protein (MAP) kinase al losteric inhibitors are useful for treatment and/or prophylaxis of degenerative diseases of the nervous system. Compounds are used in a method for treatment and/or prophylaxis of the diseases and for use in therapy in general. The compounds bind to the region composed of amino acids at positions 170-199 of Mitogen-activated protein kinase 14 (Uniprot accession nr Q16539 or SEQ ID No 1) and/or Mitogen-activated protein kinase 11 (Uniprot accession nr Q15759 or SEQ ID No 2), SEQ ID NO.1 and SEQ ID NO.2 being the amino acid sequences of MAPK14 (?38?) and MAPK11 (?38?), respectively. The specific region composed of amino acids at positions 170-199 is herein disclosed as SEQ ID HO.4 for Mitogen-activated protein kinase 14 and SEQ ID NO.5 for Mitogen-activated protein kinase 11 and are believed to be new inhibitory binding sites.

Abstract: A shower head valve may be alternated between a high flow configuration to a low flow configuration. A valve body in the invention has a flow inlet, a flow outlet, and a communication portion formed between the flow inlet and the flow outlet. A ball is disposed within the communication portion of the valve body, where the ball is an oblong spheroid having a first axis and a second axis, with the first axis perpendicular to the second axis. The ball has a first passage axially aligned with the first axis and a second passage axially aligned with the second axis. The ball is positionable from a first position in which the first passage is in alignment with the flow inlet and the flow outlet, to a second position in which the second passage is in alignment with the flow inlet and the flow outlet.

Abstract: p38 and JNK mitogen activated protein (MAP) kinase al losteric inhibitors are useful for treatment and/or prophylaxis of degenerative diseases of the nervous system. Compounds are used in a method for treatment and/or prophylaxis of the diseases and for use in therapy in general. The compounds bind to the region composed of amino acids at positions 170-199 of Mitogen-activated protein kinase 14 (Uniprot accession nr Q16539 or SEQ ID No 1) and/or Mitogen-activated protein kinase 11 (Uniprot accession nr Q15759 or SEQ ID No 2), SEQ ID NO.1 and SEQ ID NO.2 being the amino acid sequences of MAPK14 (?38?) and MAPK11 (?38?), respectively. The specific region composed of amino acids at positions 170-199 is herein disclosed as SEQ ID HO.4 for Mitogen-activated protein kinase 14 and SEQ ID NO.5 for Mitogen-activated protein kinase 11 and are believed to be new inhibitory binding sites.

Abstract: The present invention relates to a method and system for automatically detecting faults in a rotating shaft. The invention comprises the steps of: acquiring a vibration signal from the rotating shaft by means of at least one sensor; processing the signal acquired by the sensor in the time domain and in the frequency domain by means of a processor, obtaining energy measurements of the acquired signal as a result of said processing; comparing in the processor the energy measurements with previously established energy patterns; and finally determining if there is any fault in the rotating shaft based on the comparison between the energy measurements and the previously established patterns.

Abstract: The present invention provides new p38 mitogen activated protein (MAP) kinase allosteric inhibitors which are useful for the treatment of p38 mediated diseases such as inflammatory diseases, e.g. rheumatoid arthritis, osteoarthritis, psoriatic arthritis, pain, musculoskeletal system inflammation and musculoskeletal system aging. The present invention thus provides compounds for use in a method for treatment of inflammatory diseases, as well as for use in therapy in general, wherein the compound binds to the region composed of amino acids at positions 170-199 of Mitogen-activated protein kinase 14 (Uniprot accession nr Q16539 or SEQ ID No 1) and/or Mitogen-activated protein kinase 11 (Uniprot accession nr Q15759 or SEQ ID No 2), SEQ ID NO. 1 and SEQ ID NO. 2 being the amino acid sequences of MAPK14 (p38cx) and MAPK11 (p38?), respectively. The specific region composed of amino acids at positions 170-199 is herein disclosed as SEQ ID NO. 4 for Mitogen-activated protein kinase 14 and SEQ ID NO.

Abstract: A rocket stage for a spacecraft includes an engine, a tank for storing a fuel and an oxidizer for combustion in the engine, a rocket stage primary structure, and an engine thrust frame that connects and transmits forces between the engine and the primary structure. The engine thrust frame includes at least an internal part thereof arranged internally within the tank. This internal part of the engine thrust frame forms an imperforate partition that divides an interior space of the tank into at least two chambers for storing the fuel and the oxidizer separately from one another. Propellant management devices including liquid guide vanes and refillable liquid reservoirs may be provided in connection with the partition in the tank interior space.

Abstract: The present invention relates to an activator of the calcineurin subunit A?1 isofomi (CnA?1) or of the C-terminal domain of the calcineurin subunit A?1 isofomi (CnA?1) for the production of a medicament for the modulation of myocardial growth without adversely affecting contractile function.

Abstract: Portable spectrophotometer and method for characterizing solar collector tubes for simultaneously and on-field characterizing reflection and transmission coefficients. This device includes all the components needed to take this measurement, such as a module that takes the measurement of the reflection coefficient (R) of the inner tube (1?), a module that takes the measurement of transmission coefficient (T) of the outer tube (1?), an electronic data acquisition and processing system (12), an external computer (13) for controlling the device and sending the measured data (17) and a communication system (15) between device and the computer (13).

Abstract: A rocket stage for a spacecraft includes an engine, a tank for storing a fuel and an oxidizer for combustion in the engine, a rocket stage primary structure, and an engine thrust frame that connects and transmits forces between the engine and the primary structure. The engine thrust frame includes at least an internal part thereof arranged internally within the tank. This internal part of the engine thrust frame forms an imperforate partition that divides an interior space of the tank into at least two chambers for storing the fuel and the oxidizer separately from one another. Propellant management devices including liquid guide vanes and refillable liquid reservoirs may be provided in connection with the partition in the tank interior space.

Abstract: Methods and systems are disclosed for a server for app development. The server includes a memory, a network communication interface, and a controller. The controller is configured to receive user input from users of the electronic devices, the user input indicative of requests for searches of the stored profiles, send results of the searches of the stored profiles to the users of the electronic devices, receive requests from the users to send invitations to other users to join a virtual app development team, send invitations to the other users to join the virtual app development team, receive acceptance information from one or more of the other users, create a virtual app development team based on the acceptance information, and configure a section in the memory accessible to the virtual app development team and dedicated for development of an app.

Abstract: Portable spectrophotometer and method for characterizing solar collector tubes for simultaneously and on-field characterizing reflection and transmission coefficients. This device includes all the components needed to take this measurement, such as a module that takes the measurement of the reflection coefficient (R) of the inner tube (1?), a module that takes the measurement of transmission coefficient (T) of the outer tube (1?), an electronic data acquisition and processing system (12), an external computer (13) for controlling the device and sending the measured data (17) and a communication system (15) between device and the computer (13).

Abstract: The invention relates to administration of an anti-CTLA-4 antibody, particularly human antibodies to human CTLA-4, such as those having amino acid sequences of antibodies 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, 11.2.1, 11.6.1, 11.7.1, 12.3.1.1, 12.9.1.1, and MDX-010, in combination with an immunostimulatory nucleotide, i.e., CpG ODN PF3512676, for treatment of cancer. The invention relates to administering a combination of an anti-CTLA-4 antibody and CpG ODN PF3512676 as neoadjuvant, adjuvant, first-line, second-line, and third-line therapy of cancer, whether localized or metastasized, and at any point(s) along the disease continuum (e.g., at any stage of the cancer).

Abstract: The invention relates to administration of an anti-CTLA-4 antibody, particularly human antibodies to human CTLA-4, such as those having amino acid sequences of antibodies 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, 11.2.1, 11.6.1, 11.7.1, 12.3.1.1, 12.9.1.1, and MDX-010, in combination with an immunostimulatory nucleotide, i.e, CpG ODN PF3512676, for treatment of cancer. The invention relates to administering a combination of an anti-CTLA-4 antibody and CpG ODN PF3512676 as neoadjuvant, adjuvant, first-line, second-line, and third-line therapy of cancer, whether localized or metastasized, and at any point(s) along the disease continuum (e.g, at any stage of the cancer).

Abstract: The invention relates to administration of an anti-CTLA4 antibody, particularly human antibodies to human CTLA4, such as those having amino acid sequences of antibodies 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, ticilimumab (also referred to as 11.2.1 or CP-675,206), 11.6.1, 11.7.1, 12.3.1.1, 12.9.1.1, and ipilimumab (also referred to as 10D1 or MDX-010), in combination with an indolinone receptor tyrosine kinase inhibitor (RTKI), e.g., N-[2-diethylamino]ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (compound 1), N-[2-(ethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (compound 2), and 5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (compound 3), for treatment of cancer.

Abstract: The invention relates to methods for treating prostate cancer comprising administration of an anti-CTLA4 antibody, or an antigen-binding portion thereof, particularly a human antibody to human CTLA4, e.g., antibody 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, ticilimumab (also known as 11.2.1), 11.6.1, 11.7.1, 12.3.1.1, 12.9.1.1, and ipilimumab (also known as MDX-010 and 10D1), in combination with hormonal therapy. Hormonal therapy agents include, inter alia, an anti-androgen (e.g., megestrol, cyproterone, flutamide, nilutamide, and bicalutamide), a GnRH antagonist (e.g., abarelix and histrelin), and a LH-RH agonist (e.g., leuprolide, goserelin, and buserelin). The invention relates to neoadjuvant therapy, adjuvant therapy, therapy for rising PSA, first-line therapy, second-line therapy, and third-line therapy of prostate cancer, whether localized or metastasized.

Abstract: A socket wrench apparatus for applying enhanced torque having a first ratchet head which has a first ratchet mechanism therein and a first rotatable generally rectangular drive outwardly extending from the first ratchet mechanism. A first tubular handle is connected to the first ratchet head. The first tubular handle terminates at a first free distal end. The first free distal end has a square hole therein.

Abstract: The invention relates to treatment of cancer in a mammal who has undergone stem cell transplantation by administering an effective amount of a human anti-CTLA-4 antibody to the mammal. Stem cell transplantation may be allogeneic or autologous stem cell transplantation and may be preceded by a preparatory treatment such as chemotherapy. The methods of the invention may be combined with additional cancer treatments. Further, the invention relates to treatment of cancer using at least 10 mg/kg of a human anti-CTLA-4 antibody, and, more preferably, about 15-20 mg/kg of antibody.